Loss of Polk strongly amplified the sensitivity to a cisplatin-monotherapy in an isogenic lymphoma transplantation model, resulting in robust longitudinal control of tumor outgrowth in all mice, as well as a total tumor clearance in two out of nine mice. Here, POLK is linked to lymphoma.